Latest news with #LuminaPharmaceuticals
Yahoo
a day ago
- Business
- Yahoo
Lantheus Joins FIBRE Consortium with Pfizer, Lumina to Revolutionize Fibrotic Disease Treatment
Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the most undervalued US stocks according to analysts. On June 20, Lantheus Holdings announced its participation in the newly launched FIBRE Consortium, which is a collaborative initiative with Pfizer Inc. (NYSE:PFE) and Lumina Pharmaceuticals. The consortium's primary goal is to revolutionize the treatment of fibrotic diseases by using advanced imaging biomarkers. The FIBRE (Fibrosis Imaging Biomarker Research & Evaluation) Consortium aims to accelerate biomarker validation and reduce the costs of clinical trials for fibrotic diseases through innovative imaging technologies. Lantheus's contribution includes supplying LNTH-1363S, which is a PET tracer targeting Fibroblast Activation Protein/FAP. FAP is a protein expressed exclusively by activated fibroblasts. A medical professional performing a pulmonary function assessment on a patient. This biomarker, along with Lumina's [⁶⁸Ga]CBP8 PET/MRI tracer for Collagen Type I, will enable the quantification of fibrosis burden and treatment response within weeks, and potentially reduce trial durations by 60% and costs by ~$400 million. Initial studies will focus on Metabolic Dysfunction-Associated Steatohepatitis/MASH, with potential expansion into other fibrotic conditions. Lantheus Holdings Inc. (NASDAQ:LNTH) develops, manufactures, and commercializes diagnostic and therapeutic products that assist in the diagnosis and treatment of heart, cancer, and other diseases. While we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
a day ago
- Business
- Yahoo
Lantheus Joins FIBRE Consortium with Pfizer, Lumina to Revolutionize Fibrotic Disease Treatment
Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the most undervalued US stocks according to analysts. On June 20, Lantheus Holdings announced its participation in the newly launched FIBRE Consortium, which is a collaborative initiative with Pfizer Inc. (NYSE:PFE) and Lumina Pharmaceuticals. The consortium's primary goal is to revolutionize the treatment of fibrotic diseases by using advanced imaging biomarkers. The FIBRE (Fibrosis Imaging Biomarker Research & Evaluation) Consortium aims to accelerate biomarker validation and reduce the costs of clinical trials for fibrotic diseases through innovative imaging technologies. Lantheus's contribution includes supplying LNTH-1363S, which is a PET tracer targeting Fibroblast Activation Protein/FAP. FAP is a protein expressed exclusively by activated fibroblasts. A medical professional performing a pulmonary function assessment on a patient. This biomarker, along with Lumina's [⁶⁸Ga]CBP8 PET/MRI tracer for Collagen Type I, will enable the quantification of fibrosis burden and treatment response within weeks, and potentially reduce trial durations by 60% and costs by ~$400 million. Initial studies will focus on Metabolic Dysfunction-Associated Steatohepatitis/MASH, with potential expansion into other fibrotic conditions. Lantheus Holdings Inc. (NASDAQ:LNTH) develops, manufactures, and commercializes diagnostic and therapeutic products that assist in the diagnosis and treatment of heart, cancer, and other diseases. While we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
